What's Happening?
Corsair Pharma, a biopharmaceutical company, has announced three presentations at the Pulmonary Hypertension Association meeting in Dallas, Texas, from June 11-14, 2026. The presentations will focus on the TRX-248 Transdermal System, an investigational
once-daily patch for treating pulmonary arterial hypertension (PAH). The Phase 1 clinical data showed positive results in pharmacokinetics, tolerability, and dosing from healthy volunteers. The transdermal patch is designed to provide continuous systemic exposure to treprostinil, a standard treatment for PAH, by delivering an inactive prodrug that converts to active treprostinil in the liver. The presentations will include a poster session by Dr. Bobby Singh, a forum presentation by Dr. R. James White, and a product theater discussion by Dr. White and Dr. Murali Chakinala.
Why It's Important?
The development of the TRX-248 Transdermal System is significant as it offers a potential new treatment option for PAH, a serious and progressive disease affecting approximately 45,000 patients in the U.S. Current treatments improve function and outcomes but have limitations, particularly with prostanoids, which many patients are unable or unwilling to use. The transdermal system could address this unmet need by providing a more convenient and less invasive administration method. The U.S. market for prostacyclin treatments for PAH is valued at around $3.3 billion annually, indicating a substantial economic impact if the new system proves successful.
What's Next?
Following the Phase 1 results, Corsair Pharma plans to continue the clinical development of the TRX-248 Transdermal System. The company intends to pursue a 505(b)(2) regulatory pathway, which allows for a streamlined approval process for new versions of approved drugs. This could expedite the availability of the transdermal system to patients. The presentations at the conference aim to highlight the potential benefits and address current challenges in treprostinil administration, setting the stage for further research and development.
